
Aparna Raj Parikh MD FASCO
Gastrointestinal Cancer, Hematologic Oncology
Associate Professor of Medicine, Harvard Medical School Medical Director of the Young Adult Colorectal Cancer Program Director of Colorectal Cancer Medical Oncology Research Director of the Global Cancer Care Program
Join to View Full Profile
55 Fruit St.Massachusetts General HospitalBoston, MA 02114
Phone+1 617-726-2862
Fax+1 617-724-7441
Dr. Parikh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Aparna Parikh is an oncologist in Boston, MA and is affiliated with Massachusetts General Hospital. She received her medical degree from Indiana University School of Medicine and completed residency at the MGH and fellowship at UCSF. She specializes in gastrointestinal cancer and has an interest in developmental therapeutics ad liquid biopsies. She also has a background and interest in global health.
Education & Training
- University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2012 - 2014
- Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2009 - 2012
- Indiana University School of MedicineClass of 2009
Certifications & Licensure
- CA State Medical License 2012 - Present
- MA State Medical License 2016 - 2026
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Start of enrollment: 2017 Oct 31
- Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer Start of enrollment: 2020 Apr 16
- A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali Start of enrollment: 2018 Jan 01
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- Long-term Outcomes of Definitive Chemoradiation With Proton Therapy for Treatment of Carcinoma of the Anal Canal: Combined Analysis of Two Prospective Trials.Grace Lee, Bailey Nelson, Julie Koenig, John P Plastaras, James M Metz
International Journal of Radiation Oncology, Biology, Physics. 2025-05-01 - Genetic Polymorphisms in MHC Classes I and II Predict Outcomes in Metastatic Colorectal Cancer.Pooja Mittal, Francesca Battaglin, Yan Yang, Shivani Soni, Sebastian Stintzing
International Journal of Molecular Sciences. 2025-03-12 - Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A Position Paper by the National Cancer Institute GI Oncology Circulating Tumor DNA Working Group.Lakshmi Rajdev, Gentry G King, Christopher H Lieu, Stacey A Cohen, Shubham Pant
JCO Precision Oncology. 2025-03-01
Journal Articles
- Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic CancerHarvey J Mamon, Paul L Nguyen, Theodore S Hong, Aparna Parikh, Jennifer Y Wo, Rinaa S Punglia, Cristina Ferrone, Ryan D Nipp, Annals of Surgical Oncology
Lectures
- Phase II study of lamivudine in p53 mutant metastatic colorectal cancer (mCRC).ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020
- The role of circulating tumor DNA (ctDNA), tumor markers (TMs), and patient-reported outcomes (PROs) in predicting treatment response in patients with metastatic gastr...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Press Mentions
- NCCN Clinical Practice Guidelines in Oncology: 2023 UpdatesMay 19th, 2023
- Investigating the Use of Circulating Tumor DNA in Early-Stage Colon CancerOctober 7th, 2022
- New Cancer Screen, Same Issues: Can New Test Be Trusted?September 15th, 2022
- Join now to see all
Grant Support
- Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patientsMASSACHUSETTS GENERAL HOSPITAL2022–2027
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: